scPharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
John Tucker
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 32.8% |
| CEO tenure | 7.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | no data |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?
Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
Jun 27The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 16Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Nov 25scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
Oct 20FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
Oct 10Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Jan 11Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Sep 02scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
Aug 26Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like
Mar 09How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?
Nov 24
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$61m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$2m | US$604k | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$50m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$2m | US$580k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$2m | US$550k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$2m | US$531k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$35m |
| Jun 30 2020 | n/a | n/a | -US$32m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | US$1m | US$514k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$27m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$29m |
| Dec 31 2018 | US$1m | US$494k | -US$29m |
| Sep 30 2018 | n/a | n/a | -US$31m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$2m | US$380k | -US$24m |
Compensation vs Market: John's total compensation ($USD1.84M) is about average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Tucker (61 yo)
7.7yrs
Tenure
US$1,838,662
Compensation
Mr. John H. Tucker has been the Chief Executive Officer and President of scPharmaceuticals Inc. (alternate name: scPharmaceuticals LLC) since January 30, 2017 and serves as its Principal Executive Officer...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.7yrs | US$1.84m | 0.18% $ 476.8k | |
| Independent Director | 9.8yrs | US$184.55k | 0.11% $ 286.4k | |
| Independent Chairman of the Board | 8.3yrs | US$227.05k | 0.010% $ 26.3k | |
| Independent Director | 10.5yrs | US$189.55k | 0% $ 0 | |
| Independent Director | 6.8yrs | US$187.05k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$182.05k | 0% $ 0 | |
| Independent Director | 6.2yrs | US$187.05k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$197.05k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$187.05k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.8yrs
Average Tenure
63yo
Average Age
Experienced Board: SCPH's board of directors are considered experienced (6.8 years average tenure).